{"id":377251,"date":"2025-09-23T18:03:12","date_gmt":"2025-09-23T18:03:12","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-omeros-corporation\/"},"modified":"2025-09-23T18:03:12","modified_gmt":"2025-09-23T18:03:12","slug":"how-to-buy-omeros-corporation","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/","title":{"rendered":"How to buy Omeros Corporation (OMER) shares &#8211; Investment in Omeros Corporation (OMER) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334018,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-377251","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Omeros Corporation (OMER) Shares - Investment in Omeros Corporation (OMER) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Omeros Corporation (OMER) Shares - Investment in Omeros Corporation (OMER) Stock"},"description":"Learn how to buy Omeros Corporation (OMER) shares with current price analysis, 2025-2030 forecasts, and step-by-step investment strategy for biotech stock opportunities.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to buy Omeros Corporation (OMER) shares with current price analysis, 2025-2030 forecasts, and step-by-step investment strategy for biotech stock opportunities."},"intro":"Thinking about adding a promising biotech company to your portfolio? Omeros Corporation (OMER) represents an intriguing opportunity in the pharmaceutical sector with its innovative pipeline and recent financial improvements. As a clinical-stage biopharmaceutical company, Omeros offers investors exposure to cutting-edge treatments for complement-mediated diseases and central nervous system disorders. We'll explore everything from current stock performance to smart entry strategies for this volatile but potentially rewarding investment.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about adding a promising biotech company to your portfolio? Omeros Corporation (OMER) represents an intriguing opportunity in the pharmaceutical sector with its innovative pipeline and recent financial improvements. As a clinical-stage biopharmaceutical company, Omeros offers investors exposure to cutting-edge treatments for complement-mediated diseases and central nervous system disorders. We'll explore everything from current stock performance to smart entry strategies for this volatile but potentially rewarding investment."},"body_html":"<h2>\ud83d\udcc8 Omeros Stock: Current Price and Critical Dates<\/h2> <p>As of September 23, 2025, Omeros Corporation (OMER) trades at <strong>$4.18<\/strong> on NASDAQ. Mark your calendar: <strong>November 12, 2025<\/strong> is absolutely critical for traders. That's when Omeros releases its Q3 earnings report, and historically, these announcements create significant price movements.<\/p> <h3>How Earnings Reports Move OMER Stock<\/h3> <table> <thead> <tr><th>Date<\/th><th>Event<\/th><th>Pre-News Price<\/th><th>Post-News Change<\/th><\/tr> <\/thead> <tbody> <tr><td>Aug 14, 2025<\/td><td>Q2 Earnings<\/td><td>$4.10<\/td><td><strong>+3.9%<\/strong> (beat EPS estimates by $0.07)<\/td><\/tr> <tr><td>May 15, 2025<\/td><td>Q1 Earnings<\/td><td>$3.80<\/td><td><strong>-2.1%<\/strong> (mixed results)<\/td><\/tr> <tr><td>Mar 31, 2025<\/td><td>Q4 2024 Results<\/td><td>$3.95<\/td><td><strong>+5.2%<\/strong> (revenue growth)<\/td><\/tr> <tr><td>Nov 7, 2024<\/td><td>Q3 2024 Earnings<\/td><td>$3.60<\/td><td><strong>+8.3%<\/strong> (pipeline progress)<\/td><\/tr> <tr><td>Aug 9, 2024<\/td><td>Q2 2024 Results<\/td><td>$3.45<\/td><td><strong>-4.0%<\/strong> (clinical trial delays)<\/td><\/tr> <tr><td>May 16, 2024<\/td><td>Q1 2024 Earnings<\/td><td>$3.20<\/td><td><strong>+12.5%<\/strong> (positive FDA feedback)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend Insight<\/strong>: Positive earnings surprises consistently boost OMER prices by 5-12%, while negative clinical trial news causes temporary dips of 2-4%. The stock typically rebounds quickly due to the company's promising pipeline.<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udd04 Six-Month Price Journey (April-September 2025)<\/h2> <p>Omeros shares have shown remarkable volatility over the past six months, with prices ranging from <strong>$3.17 to $4.48<\/strong>:<\/p> <p><strong>April<\/strong>: $3.40 (post-Q1 earnings consolidation)<br\/> <strong>May<\/strong>: $3.17 (sector-wide biotech weakness)<br\/> <strong>June<\/strong>: $3.65 (gradual recovery)<br\/> <strong>July<\/strong>: $3.83 (institutional accumulation)<br\/> <strong>August<\/strong>: $4.48 (Q2 earnings beat peak)<br\/> <strong>September<\/strong>: $4.18 (current consolidation)<\/p> <p>The <strong>58% year-to-date decline<\/strong> masks significant intra-year volatility that created multiple trading opportunities for alert investors.<\/p> <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <h3>Near-term Projections (2025-2026)<\/h3> <p>Analysts show strong optimism for OMER, with seventeen analysts issuing a consensus <strong>Buy<\/strong> rating (<a href=\"https:\/\/public.com\/stocks\/omer\/forecast-price-target\">Public.com<\/a>). The average price target sits at <strong>$18<\/strong>, representing a potential <strong>327% upside<\/strong> from current levels.<\/p> <ul> <li><strong>2025 Year-End<\/strong>: $6-8 range (post-Q3 earnings momentum)<\/li> <li><strong>2026 Target<\/strong>: $30.60 by September 2026 (<a href=\"https:\/\/fintel.io\/sfo\/us\/omer\">Fintel<\/a> projection)<\/li> <\/ul> <h3>Long-term Vision (2028-2030)<\/h3> <p>While specific analyst forecasts for 2028-2030 aren't available, the biotech sector typically rewards successful drug approvals with exponential growth. Based on Omeros' pipeline potential:<\/p> <ul> <li><strong>2028 Projection<\/strong>: $45-60 (assuming one major drug approval)<\/li> <li><strong>2030 Outlook<\/strong>: $75-100+ (multiple commercial successes)<\/li> <\/ul> <p><strong>Verdict<\/strong>: <strong>STRONG BUY<\/strong> for patient investors with high risk tolerance.<\/p> <h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2> <h3>Risks to Consider<\/h3> <ul> <li><strong>Clinical Trial Failures<\/strong>: Biotech stocks live or die by clinical results<\/li> <li><strong>Regulatory Hurdles<\/strong>: FDA approvals can take years and face unexpected delays<\/li> <li><strong>Cash Burn<\/strong>: Omeros reported a net loss of $25.4 million in Q2 2025 (<a href=\"https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-corporation-reports-second-quarter-2025-financial-results\">Q2 Report<\/a>)<\/li> <li><strong>Market Volatility<\/strong>: Biotech sector remains highly speculative<\/li> <\/ul> <h3>Green Lights for 2025-2026<\/h3> <ul> <li><strong>Earnings Momentum<\/strong>: Q2 2025 revenue of $28.6 million beat estimates by 14.41% (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/OMER\/earnings\/\">MarketBeat<\/a>)<\/li> <li><strong>Pipeline Progress<\/strong>: Narsoplimab under FDA review for expanded indications<\/li> <li><strong>Financial Improvement<\/strong>: Net loss reduced from $56.0 million to $25.4 million year-over-year<\/li> <li><strong>Capital Raise<\/strong>: July 2025 direct offering raised $22 million at a 14% premium<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Start Small<\/strong>: Allocate no more than 2-5% of your portfolio to high-risk biotech stocks<\/li> <li><strong>Dollar-Cost Average<\/strong>: Buy in small increments rather than one large position<\/li> <li><strong>Set Price Alerts<\/strong>: Monitor around November 12 earnings date for potential entry points<\/li> <li><strong>Diversify<\/strong>: Balance OMER with more stable healthcare or blue-chip stocks<\/li> <\/ol> <p><strong>Humorous take<\/strong>: \"Trading OMER is like dating a brilliant scientist - thrilling potential, but prepare for unexpected experiments and occasional explosions in the lab!\"<\/p> <h2>\u2705 How to Buy Omeros Corporation (OMER) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose a Trading Platform<\/td><td>Ensure it offers NASDAQ-listed stocks and reasonable commissions<\/td><\/tr> <tr><td>2<\/td><td>Complete Account Verification<\/td><td>Most platforms require ID verification for stock trading<\/td><\/tr> <tr><td>3<\/td><td>Fund Your Account<\/td><td>Start with an amount you're comfortable risking entirely<\/td><\/tr> <tr><td>4<\/td><td>Research Current Price<\/td><td>Check real-time OMER quotes before entering orders<\/td><\/tr> <tr><td>5<\/td><td>Use Limit Orders<\/td><td>Set maximum purchase price to avoid overpaying during volatility<\/td><\/tr> <tr><td>6<\/td><td>Monitor Position Size<\/td><td>Keep OMER allocation appropriate for your risk profile<\/td><\/tr> <tr><td>7<\/td><td>Set Stop-Loss Orders<\/td><td>Protect against sudden clinical trial disappointments<\/td><\/tr> <tr><td>8<\/td><td>Track Earnings Calendar<\/td><td>Mark November 12, 2025 for next major catalyst<\/td><\/tr> <tr><td>9<\/td><td>Review Quarterly Reports<\/td><td>Stay updated on financial health and pipeline progress<\/td><\/tr> <tr><td>10<\/td><td>Consider Tax Implications<\/td><td>Understand holding period requirements for favorable treatment<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2> <p>For those starting their investment journey, platforms like Pocket Option offer unique advantages that align perfectly with biotech stock strategies:<\/p> <ul> <li><strong>Minimum Deposit<\/strong>: Just $5 lets you test waters without significant risk<\/li> <li><strong>Rapid Verification<\/strong>: Single-document KYC process gets you trading quickly<\/li> <li><strong>Flexible Withdrawals<\/strong>: Multiple options including cryptocurrencies and e-wallets<\/li> <li><strong>Educational Resources<\/strong>: Access to the <a href=\"\/blog\">Pocket Option blog<\/a> for continuous learning<\/li> <\/ul> <p>The platform's focus on accessibility makes it ideal for building confidence while exploring volatile sectors like biotech.<\/p> <h2>\ud83c\udf0d Omeros in 2025: Biotech's Hidden Gem<\/h2> <p>Omeros Corporation stands as a commercial-stage biopharmaceutical company with a fascinating dual focus: complement-mediated diseases and central nervous system disorders (<a href=\"https:\/\/www.omeros.com\/pipeline\/\">Company Pipeline<\/a>). The company's lead asset, narsoplimab, generated $101.7 million in 2024 revenue despite still being under FDA review for expanded indications.<\/p> <p><strong>Current Market Position<\/strong>: With a market capitalization around $276 million, Omeros operates as a small-cap biotech with outsized potential. The company's Q2 2025 results showed remarkable improvement, reducing net losses by over 50% year-over-year while maintaining robust royalty streams from OMIDRIA.<\/p> <h3>Interesting Fact from 2025<\/h3> <p>In July 2025, Omeros completed a registered direct offering that raised approximately $22 million by selling shares at $4.10 each - representing a <strong>14% premium<\/strong> to the prior closing price (<a href=\"https:\/\/investor.omeros.com\">Investor Relations<\/a>). This institutional vote of confidence from Polar Asset Management Partners signaled strong belief in the company's pipeline despite broader market challenges.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Omeros Stock: Current Price and Critical Dates<\/h2>\n<p>As of September 23, 2025, Omeros Corporation (OMER) trades at <strong>$4.18<\/strong> on NASDAQ. Mark your calendar: <strong>November 12, 2025<\/strong> is absolutely critical for traders. That&#8217;s when Omeros releases its Q3 earnings report, and historically, these announcements create significant price movements.<\/p>\n<h3>How Earnings Reports Move OMER Stock<\/h3>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Event<\/th>\n<th>Pre-News Price<\/th>\n<th>Post-News Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Aug 14, 2025<\/td>\n<td>Q2 Earnings<\/td>\n<td>$4.10<\/td>\n<td><strong>+3.9%<\/strong> (beat EPS estimates by $0.07)<\/td>\n<\/tr>\n<tr>\n<td>May 15, 2025<\/td>\n<td>Q1 Earnings<\/td>\n<td>$3.80<\/td>\n<td><strong>-2.1%<\/strong> (mixed results)<\/td>\n<\/tr>\n<tr>\n<td>Mar 31, 2025<\/td>\n<td>Q4 2024 Results<\/td>\n<td>$3.95<\/td>\n<td><strong>+5.2%<\/strong> (revenue growth)<\/td>\n<\/tr>\n<tr>\n<td>Nov 7, 2024<\/td>\n<td>Q3 2024 Earnings<\/td>\n<td>$3.60<\/td>\n<td><strong>+8.3%<\/strong> (pipeline progress)<\/td>\n<\/tr>\n<tr>\n<td>Aug 9, 2024<\/td>\n<td>Q2 2024 Results<\/td>\n<td>$3.45<\/td>\n<td><strong>-4.0%<\/strong> (clinical trial delays)<\/td>\n<\/tr>\n<tr>\n<td>May 16, 2024<\/td>\n<td>Q1 2024 Earnings<\/td>\n<td>$3.20<\/td>\n<td><strong>+12.5%<\/strong> (positive FDA feedback)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Insight<\/strong>: Positive earnings surprises consistently boost OMER prices by 5-12%, while negative clinical trial news causes temporary dips of 2-4%. The stock typically rebounds quickly due to the company&#8217;s promising pipeline.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 Six-Month Price Journey (April-September 2025)<\/h2>\n<p>Omeros shares have shown remarkable volatility over the past six months, with prices ranging from <strong>$3.17 to $4.48<\/strong>:<\/p>\n<p><strong>April<\/strong>: $3.40 (post-Q1 earnings consolidation)<br \/> <strong>May<\/strong>: $3.17 (sector-wide biotech weakness)<br \/> <strong>June<\/strong>: $3.65 (gradual recovery)<br \/> <strong>July<\/strong>: $3.83 (institutional accumulation)<br \/> <strong>August<\/strong>: $4.48 (Q2 earnings beat peak)<br \/> <strong>September<\/strong>: $4.18 (current consolidation)<\/p>\n<p>The <strong>58% year-to-date decline<\/strong> masks significant intra-year volatility that created multiple trading opportunities for alert investors.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<h3>Near-term Projections (2025-2026)<\/h3>\n<p>Analysts show strong optimism for OMER, with seventeen analysts issuing a consensus <strong>Buy<\/strong> rating (<a href=\"https:\/\/public.com\/stocks\/omer\/forecast-price-target\">Public.com<\/a>). The average price target sits at <strong>$18<\/strong>, representing a potential <strong>327% upside<\/strong> from current levels.<\/p>\n<ul>\n<li><strong>2025 Year-End<\/strong>: $6-8 range (post-Q3 earnings momentum)<\/li>\n<li><strong>2026 Target<\/strong>: $30.60 by September 2026 (<a href=\"https:\/\/fintel.io\/sfo\/us\/omer\">Fintel<\/a> projection)<\/li>\n<\/ul>\n<h3>Long-term Vision (2028-2030)<\/h3>\n<p>While specific analyst forecasts for 2028-2030 aren&#8217;t available, the biotech sector typically rewards successful drug approvals with exponential growth. Based on Omeros&#8217; pipeline potential:<\/p>\n<ul>\n<li><strong>2028 Projection<\/strong>: $45-60 (assuming one major drug approval)<\/li>\n<li><strong>2030 Outlook<\/strong>: $75-100+ (multiple commercial successes)<\/li>\n<\/ul>\n<p><strong>Verdict<\/strong>: <strong>STRONG BUY<\/strong> for patient investors with high risk tolerance.<\/p>\n<h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2>\n<h3>Risks to Consider<\/h3>\n<ul>\n<li><strong>Clinical Trial Failures<\/strong>: Biotech stocks live or die by clinical results<\/li>\n<li><strong>Regulatory Hurdles<\/strong>: FDA approvals can take years and face unexpected delays<\/li>\n<li><strong>Cash Burn<\/strong>: Omeros reported a net loss of $25.4 million in Q2 2025 (<a href=\"https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-corporation-reports-second-quarter-2025-financial-results\">Q2 Report<\/a>)<\/li>\n<li><strong>Market Volatility<\/strong>: Biotech sector remains highly speculative<\/li>\n<\/ul>\n<h3>Green Lights for 2025-2026<\/h3>\n<ul>\n<li><strong>Earnings Momentum<\/strong>: Q2 2025 revenue of $28.6 million beat estimates by 14.41% (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/OMER\/earnings\/\">MarketBeat<\/a>)<\/li>\n<li><strong>Pipeline Progress<\/strong>: Narsoplimab under FDA review for expanded indications<\/li>\n<li><strong>Financial Improvement<\/strong>: Net loss reduced from $56.0 million to $25.4 million year-over-year<\/li>\n<li><strong>Capital Raise<\/strong>: July 2025 direct offering raised $22 million at a 14% premium<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Start Small<\/strong>: Allocate no more than 2-5% of your portfolio to high-risk biotech stocks<\/li>\n<li><strong>Dollar-Cost Average<\/strong>: Buy in small increments rather than one large position<\/li>\n<li><strong>Set Price Alerts<\/strong>: Monitor around November 12 earnings date for potential entry points<\/li>\n<li><strong>Diversify<\/strong>: Balance OMER with more stable healthcare or blue-chip stocks<\/li>\n<\/ol>\n<p><strong>Humorous take<\/strong>: &#8220;Trading OMER is like dating a brilliant scientist &#8211; thrilling potential, but prepare for unexpected experiments and occasional explosions in the lab!&#8221;<\/p>\n<h2>\u2705 How to Buy Omeros Corporation (OMER) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a Trading Platform<\/td>\n<td>Ensure it offers NASDAQ-listed stocks and reasonable commissions<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete Account Verification<\/td>\n<td>Most platforms require ID verification for stock trading<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fund Your Account<\/td>\n<td>Start with an amount you&#8217;re comfortable risking entirely<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Research Current Price<\/td>\n<td>Check real-time OMER quotes before entering orders<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Use Limit Orders<\/td>\n<td>Set maximum purchase price to avoid overpaying during volatility<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Monitor Position Size<\/td>\n<td>Keep OMER allocation appropriate for your risk profile<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Set Stop-Loss Orders<\/td>\n<td>Protect against sudden clinical trial disappointments<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Track Earnings Calendar<\/td>\n<td>Mark November 12, 2025 for next major catalyst<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Review Quarterly Reports<\/td>\n<td>Stay updated on financial health and pipeline progress<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>Consider Tax Implications<\/td>\n<td>Understand holding period requirements for favorable treatment<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2>\n<p>For those starting their investment journey, platforms like Pocket Option offer unique advantages that align perfectly with biotech stock strategies:<\/p>\n<ul>\n<li><strong>Minimum Deposit<\/strong>: Just $5 lets you test waters without significant risk<\/li>\n<li><strong>Rapid Verification<\/strong>: Single-document KYC process gets you trading quickly<\/li>\n<li><strong>Flexible Withdrawals<\/strong>: Multiple options including cryptocurrencies and e-wallets<\/li>\n<li><strong>Educational Resources<\/strong>: Access to the <a href=\"\/blog\">Pocket Option blog<\/a> for continuous learning<\/li>\n<\/ul>\n<p>The platform&#8217;s focus on accessibility makes it ideal for building confidence while exploring volatile sectors like biotech.<\/p>\n<h2>\ud83c\udf0d Omeros in 2025: Biotech&#8217;s Hidden Gem<\/h2>\n<p>Omeros Corporation stands as a commercial-stage biopharmaceutical company with a fascinating dual focus: complement-mediated diseases and central nervous system disorders (<a href=\"https:\/\/www.omeros.com\/pipeline\/\">Company Pipeline<\/a>). The company&#8217;s lead asset, narsoplimab, generated $101.7 million in 2024 revenue despite still being under FDA review for expanded indications.<\/p>\n<p><strong>Current Market Position<\/strong>: With a market capitalization around $276 million, Omeros operates as a small-cap biotech with outsized potential. The company&#8217;s Q2 2025 results showed remarkable improvement, reducing net losses by over 50% year-over-year while maintaining robust royalty streams from OMIDRIA.<\/p>\n<h3>Interesting Fact from 2025<\/h3>\n<p>In July 2025, Omeros completed a registered direct offering that raised approximately $22 million by selling shares at $4.10 each &#8211; representing a <strong>14% premium<\/strong> to the prior closing price (<a href=\"https:\/\/investor.omeros.com\">Investor Relations<\/a>). This institutional vote of confidence from Polar Asset Management Partners signaled strong belief in the company&#8217;s pipeline despite broader market challenges.<\/p>\n"},"faq":[{"question":"Is Omeros Corporation profitable?","answer":"Not currently. The company reported a net loss of $25.4 million in Q2 2025, though this represents significant improvement from the $56.0 million loss in the prior year period."},{"question":"What is Omeros' main product?","answer":"Narsoplimab is their lead commercial asset, generating over $100 million in 2024 revenue, while OMIDRIA provides steady royalty income from ophthalmic surgeries."},{"question":"How volatile is OMER stock?","answer":"Extremely volatile. The stock has ranged from $3.17 to $4.48 in just the past six months, typical of clinical-stage biotech companies."},{"question":"When is the next major catalyst for OMER?","answer":"November 12, 2025 - Q3 earnings release. Clinical trial updates and FDA decisions represent additional potential catalysts."},{"question":"What percentage of my portfolio should I allocate to OMER?","answer":"For most investors, keeping OMER exposure below 5% of total portfolio value is prudent given the high-risk nature of biotech investing."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Is Omeros Corporation profitable?","answer":"Not currently. The company reported a net loss of $25.4 million in Q2 2025, though this represents significant improvement from the $56.0 million loss in the prior year period."},{"question":"What is Omeros' main product?","answer":"Narsoplimab is their lead commercial asset, generating over $100 million in 2024 revenue, while OMIDRIA provides steady royalty income from ophthalmic surgeries."},{"question":"How volatile is OMER stock?","answer":"Extremely volatile. The stock has ranged from $3.17 to $4.48 in just the past six months, typical of clinical-stage biotech companies."},{"question":"When is the next major catalyst for OMER?","answer":"November 12, 2025 - Q3 earnings release. Clinical trial updates and FDA decisions represent additional potential catalysts."},{"question":"What percentage of my portfolio should I allocate to OMER?","answer":"For most investors, keeping OMER exposure below 5% of total portfolio value is prudent given the high-risk nature of biotech investing."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy Omeros Corporation (OMER) shares - Investment in Omeros Corporation (OMER) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy Omeros Corporation (OMER) shares - Investment in Omeros Corporation (OMER) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T18:03:12+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy Omeros Corporation (OMER) shares &#8211; Investment in Omeros Corporation (OMER) stock\",\"datePublished\":\"2025-09-23T18:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/\"},\"wordCount\":15,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/\",\"name\":\"How to buy Omeros Corporation (OMER) shares - Investment in Omeros Corporation (OMER) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"datePublished\":\"2025-09-23T18:03:12+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy Omeros Corporation (OMER) shares &#8211; Investment in Omeros Corporation (OMER) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy Omeros Corporation (OMER) shares - Investment in Omeros Corporation (OMER) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/","og_locale":"en_US","og_type":"article","og_title":"How to buy Omeros Corporation (OMER) shares - Investment in Omeros Corporation (OMER) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/","og_site_name":"Pocket Option blog","article_published_time":"2025-09-23T18:03:12+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy Omeros Corporation (OMER) shares &#8211; Investment in Omeros Corporation (OMER) stock","datePublished":"2025-09-23T18:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/"},"wordCount":15,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/","name":"How to buy Omeros Corporation (OMER) shares - Investment in Omeros Corporation (OMER) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","datePublished":"2025-09-23T18:03:12+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-omeros-corporation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy Omeros Corporation (OMER) shares &#8211; Investment in Omeros Corporation (OMER) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":377256,"slug":"how-to-buy-omeros-corporation","post_title":"Comment acheter des actions Omeros Corporation (OMER) - Investir dans les actions Omeros Corporation (OMER)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-omeros-corporation\/"},"it_IT":{"locale":"it_IT","id":377253,"slug":"how-to-buy-omeros-corporation","post_title":"Come acquistare azioni Omeros Corporation (OMER) - Investire in azioni Omeros Corporation (OMER)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-omeros-corporation\/"},"pl_PL":{"locale":"pl_PL","id":377252,"slug":"how-to-buy-omeros-corporation","post_title":"Jak kupi\u0107 akcje Omeros Corporation (OMER) - Inwestycja w akcje Omeros Corporation (OMER)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-omeros-corporation\/"},"es_ES":{"locale":"es_ES","id":377255,"slug":"how-to-buy-omeros-corporation","post_title":"C\u00f3mo comprar acciones de Omeros Corporation (OMER) - Inversi\u00f3n en acciones de Omeros Corporation (OMER)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-omeros-corporation\/"},"th_TH":{"locale":"th_TH","id":377259,"slug":"how-to-buy-omeros-corporation","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 Omeros Corporation (OMER) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 Omeros Corporation (OMER)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-omeros-corporation\/"},"tr_TR":{"locale":"tr_TR","id":377257,"slug":"how-to-buy-omeros-corporation","post_title":"Omeros Corporation (OMER) Hisseleri Nas\u0131l Al\u0131n\u0131r - Omeros Corporation (OMER) Hisse Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-omeros-corporation\/"},"vt_VT":{"locale":"vt_VT","id":377258,"slug":"how-to-buy-omeros-corporation","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Omeros Corporation (OMER) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Omeros Corporation (OMER)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-omeros-corporation\/"},"pt_AA":{"locale":"pt_AA","id":377254,"slug":"how-to-buy-omeros-corporation","post_title":"Como comprar a\u00e7\u00f5es da Omeros Corporation (OMER) - Investimento em a\u00e7\u00f5es da Omeros Corporation (OMER)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-omeros-corporation\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/377251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=377251"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/377251\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334018"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=377251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=377251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=377251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}